Reduction of heparin dose is not beneficial to platelet function

Annals of Thoracic Surgery

Volumn 70, Issue 1, 2000, Pages 186-190

  Nakajima, Takayuki ^a   Kawazoe, Kohei ^a   Ishibashi, Kazuyuki ^a   Kubota, Yoshimitsu ^a   Sasaki, Tatsuya ^a   Izumoto, Hiroshi ^a   Nitatori, Tohru ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; HEPARIN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ELECTRON MICROSCOPY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE; THROMBOCYTE COUNT;

ANTICOAGULANTS; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; HEPARIN; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0033942715     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01389-8     Document Type: Article

References (17)

1. Bannan S., Danby A., Cowan D., Ashraf S., Martin P.G. Low heparinization with heparin-bonded bypass circuits is it a safe strategy? Ann Thorac Surg. 63:1997;663-668.
2. Korn R.L., Fisher C.A., Livingston E.R., et al. Cardiopulmonary bypass, myocardial management, and support techniques. The effects of carmeda bioactive surface on human blood components during simulated extracorporeal circulation. J Thorac Cardiovasc Surg. 111:1996;1073-1084.
3. Von Segesser L.K., Weiss B.M., Pasic M., Garcia E., Turina M.I. Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg. 58:1994;391-398.
4. Borowiec J., Thelin S., Bagge L., Hultman J., Hansson H.E. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and reduction of heparin dose. Scand J Thorac Cardiovasc Surg. 26:1992;177-185.
5. Nakajima T., Osawa S., Ogawa M., et al. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment. ASAIO J. 42:1996;301-305.
6. Borowiec J.W., Bylock A., van der Linden J., Thelin S. Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass a clinical study . Ann Thorac Surg. 55:1993;1540-1545.
7. Gravlee G.P., Haddon W.S., Rothberger H.K., et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg. 99:1990;518-527.
8. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 9:1972;248-257.
9. Salzman E.W., Rosenberg R.D., Smith M.H., Lindon J.N., Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 65:1980;64-73.
10. John L.C.H., Rees G.M., Kovacs I.B. Inhibition of platelet function by heparin. An etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg. 105:1993;816-822.
11. Chong B.H., Ismail F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol. 43:1989;245-251.
12. Mendeloff E.N., Liang I.Y.S., Swain J.A., Clark R.E. Thromboxane A2 receptor-specific antagonism in hypothermic cardiopulmonary bypass. Ann Thorac Surg. 57:1994;999-1006.
13. Cook J.J., Niewiarowski S., Yan Z., et al. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation. 85:1992;1102-1109.
14. Musial J., Niewiarowski S., Rucinski B., et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation. 82:1990;261-273.
15. Berliner S., Fishelson Z., Wasserman L., Pinkhas J., Aronson M. Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation. Biomed Pharmacother. 42:1988;69-72.
16. Ovrum E., Mollnes T.E., Fosse E., et al. Complement and granulocyte activation in two different types of the heparinized extracorporeal circuits. J Thorac Cardiovasc Surg. 110:1995;1623-1632.
17. Edmunds L.H. Jr. Surface-bound heparin. Panacea or peril? Ann Thorac Surg. 58:1994;285-286.